NCT03710564 · Interventional trial
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Overall registry status Terminated
Phase 3
Conditions Age-Related Macular Degeneration
Delaware Valley sites
- Novartis Investigative Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory